🔬 Dr. Omar Y. Mian's talk on optimizing therapy for Clinically Node Positive Prostate Cancer is underway! Key takeaways so far:
- 13% of new PCa cases are N+
- PSMA PET staging may increase cN1 patients
- Early ADT benefits N+ PCa
#ASTRO2023

20 years on market and now available in #latam to help the growth of nuclear medicine field.

Congrats MIM Software !

🎊🎉

La expansión en el uso de PET-PSMA vendrá de la mano de estandarización en los criterios de uso así como en el reporte.

PROMISE V 2.0 trae algunas modificaciones, entre ellas el uso de total tumor burden.

Conoce más 👇

link.springer.com/epdf/10.1007/s…

En pocas semanas un gran evento académico, multi-disciplinario, encaminado a compartir la evidencia más relevante y actualizada sobre el nuevo mundo de #teragnosis en #latam .

Nos sentimos entusiasmados de ser parte de tan importante evento.
Danny Mena - nuclear medicine

Cuál es el tiempo recomendado para realizar un #petpsma después de un tratamiento con radioterapia localizado en la próstata?

ascopubs.org/doi/abs/10.120….

UroTarget DR CARVAJAL Pablo CASTRO PEÑA

Una nueva era en #cancerdeprostata ya está presente.
La evidencia científica es contundente.
Ahora, es momento de educar a la región para un crecimiento sostenido y sustentado del método.
UroTeragLATAM UroTarget

“Why Dosimetry Matters”
SNMMI

Piet Ost Afonso Morgado Ken Herrmann prof. Stefano Fanti Wonderful! Using inductive logic to guide rationale for PSMA PET (will it change management) rather than saying we should just use CT, just because that is what the 20 year old trials used, and the PSMA might misguide through stage migration.

¹⁷⁷Lu-PSMA induced #hypocalcemia : what do we need to know? ow.ly/7Syi50OWA3n

#NuclearMedicine #ProstateCancer Louise Emmett

Outstanding turnout for our #SNMMI23 #Dosimetry Workshop this afternoon!

Guests saw MIM SurePlan™ MRT up-close, including:
• Zero-click AI auto-segmentation
• Industry-leading single-timepoint dosimetry
• Timesaving workflow automation

#MolecularRadiotherapy #SNMMI2023

🎉The countdown to #SNMMI23 is on! With an “Eye on the Patient,” we’re excited to join our fellow #NucMed professionals to improve patient care through personalized imaging solutions. Join us in Booth #6019 to learn more about a partnership that spans the #Theranostic pathway.

🌐 Discover the future of #ProstateCancer theranostics with world-class experts. 💡 Discussing Alpha #PSMA , new targets, & neuroendocrine challenges. Your voice matters - join us for a live Q&A!

🗓️July 19, 1PM PST / 9PM CET. ✨Register now: unimelb.zoom.us/webinar/regist…

Estaremos presentes 🤚 en #snmmi23 mostrando las soluciones de MIM Software .
Encuéntranos en el booth 6019 y te mostraremos las soluciones disponibles para #latam .

We’re thrilled to join you this weekend at #SNMMI23 .

Reserve a demo in booth 6019 at bit.ly/3qCMAzW .

#ImagingPersonalized #NucMed #Dosimetry #NuclearMedicine #PSMA #PETCT #SNMMI2023

Un paso fundamental antes de iniciar cualquier tratamiento, incluye la correcta selección del paciente.

SNMMI acaba de anunciar el consenso en terapias con radioisótopos (177Lu-PSMA).

SPECT-PSMA en recaída bioquímica?
✅ SPECT/CT
✅ Imagen tardía (> 15 horas)
✅ SPECT-PSMA es inferior a PET-PSMA
✅ Aplicación en recaída bioquímica? Cirugía radioguiada de rescate

Late imaging should be preferred when using [99mTc]Tc-PSMA-I&S SPECT/CT for lesion detection in early biochemical recurrence of #ProstateCancer . However, #PSMA SPECT/CT performance is clearly inferior to PSMA PET/CT. ow.ly/x5JF50OA0ae

#NuclearMedicine

🎉 Happy #ClinicalTrialsDay ! We are thrilled to announce the completion of randomisation for #UpFrontPSMA , a major milestone in advancing research for hormone-sensitive metastatic prostate cancer with Lu-177 PSMA-617. Results 2024.

Arun Azad Movember USA ANZUP Novartis

Sipping my Sunday morning coffee ☕️while reading what this excellent review what's on the horizon for #radiotheranostics #radiopharmaceuticals ☢️

✅New radionuclides (alphas!)
✅New targets/ligands
✅New platforms
✅Combination tx

Michael Hofman Ken Herrmann

It’s National Clinical Trials Day! MIM® is an important component of many #ClinicalTrials , helping researchers process imaging data and treatment planning with accuracy.

Thanks to all the clinicians who advance #RadiationOncology and #NuclearMedicine through research!